Gene therapies are very much at their preliminary stages of development, so it would make sense to keep tabs on patients whose DNA has been modified via the innovative CRISPR technique.
For some scientists in China, however, this is apparently not a priority.
The Wall Street Journal is reporting that an undisclosed number of Chinese cancer patients who have undergone experimental gene therapies aren’t being properly tracked as would be expected.
The scientists in charge of at least one trial failed to maintain ties with their patients afterwards and conduct follow-up examinations, according to the WSJ.
Indeed, follow-ups are extra critical for patients undergoing gene therapies.
Unexpected health problems stemming from gene modifications, such as autoimmune disorders, could appear later in life.